Abbott Laboratories vs. Rallybio Corporation Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | RLYB | |
|---|---|---|
| Market Cap | $182.49 billion | $85.65 million |
| Revenue (TTM) | $46.59 billion | $858,000 |
| Net Income (TTM) | $5.42 billion | $-7,817,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | RLYB | |
|---|---|---|
| P/E Ratio | 34.21 | — |
| Price / Book | 3.53 | 1.70 |
| Price / Sales | 3.92 | 99.83 |
ABT and RLYB split the valuation factors evenly.
Profitability
| ABT | RLYB | |
|---|---|---|
| Net Margin | 11.65% | -911.07% |
| Return on Equity | 10.48% | -15.55% |
ABT leads on 2 of 2 profitability factors.
Risk & Sentiment
| ABT | RLYB | |
|---|---|---|
| Short Interest | 0.57% | 0.02% |
RLYB leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RLYB overview, RLYB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.